Correlation between Regression of Postoperative CA125 Level in Epithelial Ovarian Cancer and 3-Year Progression Free Survival
Article Sidebar
Main Article Content
Abstract
Objectives: To examine the relationship between regression of postoperative cancer antigen 125 (CA 125) level in epithelial ovarian cancer and 3-year progression free survival.
Materials and Methods: A retrospective study was conducted in patients with the International Federation of Gynecology and Obstetrics (FIGO) stage I-IV epithelial ovarian cancer treated by complete surgical staging or primary debulking surgery between 2013 and 2017 at Prapokklao Hospital, Chanthaburi, Thailand. The study focused on pre-postoperative decline of serum CA 125 level. Three-year progression free survival analyses were conducted by the Kaplan-Meier method, log-rank test and multivariate Cox regression.
Results: A total of 125 epithelial ovarian cancer patients were enrolled as 38 patients with < 50% regression of CA 125, 41 patients with 50 - < 80% regression of CA 125 and 46 patients with ≥ 80% regression of CA 125. Survival analysis showed association between regression of CA 125 level and 3-year progression free survival (p < 0.001). Patients with ≥ 80% regression of CA 125 had better 3-year progression free survival than the 50 - < 80% and < 50% groups. [hazard ratio (HR) 50 - < 80% = 2.87 [95% confidence interval (CI): 0.90-9.13], HR < 50% = 5.34 [95%CI: 1.74-16.4] vs. ≥ 80% group].
Conclusion: Pre-postoperative regression of CA 125 had associated with 3-year progression free survival in patients who underwent primary surgery in epithelial ovarian cancer. The ≥ 80% CA 125 declination group recorded better survival outcome than the 50 - < 80% and < 50% groups.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Jonathan S. Berek DLB. Ovarian, fallopian tube, and peritoneal cancer. Berek and Novak’s Gynecology. 16th ed. United States: Philadelphia, Wolters Kluwer 2019;1077–110.
Committee Opinion No. 716: The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer in women at average risk. Obstet Gynecol 2017;130:e146-e9.
Yin BW, Lloyd KO. Molecular cloning of the CA 125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001;276:27371-5.
Practice Bulletin No. 174: Evaluation and management of adnexal masses. Obstet Gynecol 2016;128:e210-e26.
Morales-Vásquez F, Pedernera E, Reynaga-Obregón J, López-Basave HN, Gómora MJ, Carlón E, et al. High levels of pretreatment CA 125 are associated to improved survival in high grade serous ovarian carcinoma. J Ovarian Res 2016;9:41.
Osman N, O’Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, et al. Correlation of serum CA 125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Ir Med J 2008;101:245-7.
Yang ZJ, Zhao BB, Li L. The significance of the change pattern of serum CA 125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer. J Ovarian Res 2016;9:57.
Timmermans M, Zwakman N, Sonke GS, Van de Vijver KK, Duk MJ, van der Aa MA, et al. Perioperative change in CA 125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2019;240: 364-9.
Zwakman N, van de Laar R, Van Gorp T, Zusterzeel PL, Snijders MP, Ferreira I, et al. Perioperative changes in serum CA 125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer. J Gynecol Oncol 2017;28:e7.
Seung-Chul Y, Jong-Hyuck Y, Mi-Ok L, et al. Significance of postoperative CA125 decline after cytoreductive surgery in stage IIIC/IV ovarian cancer. J Gynecol Oncol 2009;19:169-72.
Yedema CA, Kenemans P, Thomas CM, Massuger LF, Wobbes T, Verstraeten R, et al. CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery. Eur J Cancer 1993;29a:966-71.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian Cancer, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19:191-226.